Skip to main content
main-content

24.01.2018 | Original Article – Clinical Oncology | Ausgabe 4/2018

Journal of Cancer Research and Clinical Oncology 4/2018

A comprehensive evaluation of clinicopathologic characteristics, molecular features and prognosis in lung adenocarcinoma with solid component

Zeitschrift:
Journal of Cancer Research and Clinical Oncology > Ausgabe 4/2018
Autoren:
Jing Li, Wenjie You, Difan Zheng, Bei Yan, Xiao Ma, Yunjian Pan, Yang Zhang, Yuan Li, Xuxia Shen, Xinghua Cheng, Yihua Sun, Haiquan Chen
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s00432-018-2588-6) contains supplementary material, which is available to authorized users.
Jing Li, Wenjie You and Difan Zheng contributed equally to this work.

Abstract

Purpose

We have reported that solid predominant lung adenocarcinoma according to the IASLC/ATS/ERS classification was associated with poor prognosis. However, the correlation of solid component with clinicopathological, molecular features, and prognosis in all lung adenocarcinoma patients remains unexplored.

Methods

Surgically resected lung adenocarcinomas were divided into three groups, solid predominant (solid component accounting for at least 50%), solid minor (solid component accounting for 5–45%) and solid negative. Patients’ clinicopathological characteristics, disease free survival (DFS), overall survival (OS) and molecular alterations, including EGFR, KRAS, FGFR, etc., were analyzed.

Results

Of 1098 lung adenocarcinomas, 198 were solid predominant, 132 were solid minor, and 768 were solid negative. Solid positive patients, including solid predominant and solid minor, had significantly worse DFS (p < 0.0001) and OS (p < 0.0001) compared with solid negative group, so were solid minor patients (both p < 0.0001). Cox multivariate analysis revealed that solid positive pattern was an independent predictor for DFS [hazard ratio (HR) 1.495, 95% confidence interval (CI) 1.004–2.233; p = 0.034] and OS [HR 1.561, 95% CI 1.03–2.342; p = 0.016]. The frequency of FGFR fusions was significantly higher in solid positive lung adenocarcinomas than in solid negative group (1.5 vs. 0.3%, p = 0.048). The response rate to EGFR-tyrosine kinase inhibitors (TKIs) was 66.7% in EGFR-mutated solid positive patients after recurrence.

Conclusions

This study represents the first comprehensive clinical investigation of solid component in lung adenocarcinomas, identifying solid positive pattern as an independent poor prognostic indicator in lung adenocarcinoma.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary material 1 (DOCX 25 KB)
432_2018_2588_MOESM1_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2018

Journal of Cancer Research and Clinical Oncology 4/2018 Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise